Association of Second Anti-hypertensive Agent with Outcomes in People with CKD on ACEi/ARB Therapy

BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are first-line treatment for hypertension in chronic kidney disease (CKD). However, guidelines do not recommend subsequent medication classes if additional blood pressure-lowering effect is desired. METHODS: This target trial emulation using national outpatient data from the Veterans Health Administration from January 1, 2010, to December 31, 2016, included adults with non-dialysis CKD stages G1-G5 on an ACEi/ARB who initiated treatment with a second antihypertensive medication, classified as a thiazide diuretic, loop diuretic, calcium channel blocker, or β-blocker. Outcomes included composite cardiovascular events (fatal or nonfatal myocardial infarction or stroke, hospitalization for heart failure, coronary revascularization), all-cause death, and composite kidney outcomes (dialysis initiation, kidney transplantation, sustained creatinine doubling). Clinically important characteristics were included as covariates in the analysis. RESULTS: Of 150,369 individuals already on ACEi/ARB treatment, 45,836 (30%) were prescribed a thiazide diuretic, 17,589 (12%) a loop diuretic, 33,172 (22%) a calcium channel blocker, and 53,772 (36%) a β-blocker. Those receiving thiazide diuretics and calcium channel blockers had the highest baseline blood pressure. Those receiving loop diuretics were more likely to have more advanced CKD or heart failure. Over a median (IQR) follow-up of 1282 (621, 1979) days, compared to thiazide diuretics, cardiovascular event risk was higher for calcium channel blockers, aHR 1.18 (95% CI 1.15-1.22), β-blockers, aHR 1.63 (95% CI 1.58-1.67), and loop diuretics, aHR 1.97 (95% CI 1.90-2.04). Composite kidney outcomes were also higher with calcium channel blockers, aHR 1.42 (95% CI 1.33-1.52), β-blockers, aHR 1.13 (95% CI 1.06-1.21), and loop diuretics, aHR 1.98 (95% CI 1.83-2.15). CONCLUSIONS: Adding a thiazide diuretic rather than a calcium channel blocker, β-blocker, or loop diuretic on top of ACEi/ARB treatment was associated with favorable clinical outcomes among people with CKD.

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2026-11-13
DOI
https://doi.org/10.1681/asn.0000001313
Primary Topic
Blood Pressure and Hypertension Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association of Second Anti-hypertensive Agent with Outcomes in People with CKD on ACEi/ARB Therapy

Wolfgang C. Winkelmayer­, L. Parker Gregg, S. Susan Hedayati, Vijay Nambi et al.
1 links
Journal of the American Society of Nephrology
Blood Pressure and Hypertension Studies
article

Association of Second Anti-hypertensive Agent with Outcomes in People with CKD on ACEi/ARB Therapy

Wolfgang C. Winkelmayer­, L. Parker Gregg, S. Susan Hedayati, Vijay Nambi, Sankar Dass Navaneethan, Hui Yang, Carlos A. Álvarez, Christine Vu, Aaron Perkins
article en

Abstract

BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are first-line treatment for hypertension in chronic kidney disease (CKD). However, guidelines do not recommend subsequent medication classes if additional blood pressure-lowering effect is desired. METHODS: This target trial emulation using national outpatient data from the Veterans Health Administration from January 1, 2010, to December 31, 2016, included adults with non-dialysis CKD stages G1-G5 on an ACEi/ARB who initiated treatment with a second antihypertensive medication, classified as a thiazide diuretic, loop diuretic, calcium channel blocker, or β-blocker. Outcomes included composite cardiovascular events (fatal or nonfatal myocardial infarction or stroke, hospitalization for heart failure, coronary revascularization), all-cause death, and composite kidney outcomes (dialysis initiation, kidney transplantation, sustained creatinine doubling). Clinically important characteristics were included as covariates in the analysis. RESULTS: Of 150,369 individuals already on ACEi/ARB treatment, 45,836 (30%) were prescribed a thiazide diuretic, 17,589 (12%) a loop diuretic, 33,172 (22%) a calcium channel blocker, and 53,772 (36%) a β-blocker. Those receiving thiazide diuretics and calcium channel blockers had the highest baseline blood pressure. Those receiving loop diuretics were more likely to have more advanced CKD or heart failure. Over a median (IQR) follow-up of 1282 (621, 1979) days, compared to thiazide diuretics, cardiovascular event risk was higher for calcium channel blockers, aHR 1.18 (95% CI 1.15-1.22), β-blockers, aHR 1.63 (95% CI 1.58-1.67), and loop diuretics, aHR 1.97 (95% CI 1.90-2.04). Composite kidney outcomes were also higher with calcium channel blockers, aHR 1.42 (95% CI 1.33-1.52), β-blockers, aHR 1.13 (95% CI 1.06-1.21), and loop diuretics, aHR 1.98 (95% CI 1.83-2.15). CONCLUSIONS: Adding a thiazide diuretic rather than a calcium channel blocker, β-blocker, or loop diuretic on top of ACEi/ARB treatment was associated with favorable clinical outcomes among people with CKD.

Journal of the American Society of Nephrology
Michael E. DeBakey VA Medical Center (US), Baylor College of Medicine (US), Health Services Research & Development (US), Stony Brook Medicine (US), VA North Texas Health Care System (US), Center for Innovation (US), Stony Brook University (US), The University of Texas Southwestern Medical Center (US), Texas Tech University Health Sciences Center (US)
Good health and well-being
Blood Pressure and Hypertension Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon